Skip to main content
Log in

Activated T cells and cytokine-induced CD3+CD56+ killer cells

  • REVIEW ARTICLE
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

 Over the past two decades, attempts have been made to develop immunotherapy for patients with cancer. A significant obstacle to the development of successful adoptive immunotherapy has been the availability of appropriate cytotoxic cells. Immunologic effector cells such as lymphokine-activated killer (LAK) cells, activated T cells such as tumor-infiltrating lymphocytes (TILs), and cytokine-induced killer (CIK) cells may be suitable to remove residual tumor cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 7 October 1996 / Accepted: 13 November 1996

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmidt-Wolf, G., Negrin, R. & Schmidt-Wolf, I. Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol 74, 51–56 (1997). https://doi.org/10.1007/s002770050257

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002770050257

Navigation